|
業務類別
|
Biotechnology |
|
業務概覽
|
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies. |
| 公司地址
| 21 Hickory Drive, Suite 500, Waltham, MA, USA, 02451 |
| 電話號碼
| +1 617 819-2020 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.sionnatx.com |
| 員工數量
| 59 |
| Caroline Stark Beer, M.B.A. |
Chief Business Officer |
-- |
27/04/2026 |
| Dr. Charlotte McKee, M.D. |
Chief Medical Officer |
美元 158.95K |
27/04/2026 |
| Ms. Jennifer Fitzpatrick |
Chief Legal Officer |
-- |
27/04/2026 |
| Mr. Michael Cloonan, M.B.A. |
Chief Executive Officer, President and Director |
美元 646.58K |
27/04/2026 |
| Ms. Elena H. Ridloff, C.F.A. |
Chief Financial Officer |
美元 506.68K |
27/04/2026 |
|
|
| Dr. Lucian Iancovici, M.D. |
Independent Director |
27/04/2026 |
| Dr. Marcella Kuhlman Ruddy, M.D.,M.S. |
Independent Director |
27/04/2026 |
| Dr. H. Edward Fleming, Jr,M.D. |
Independent Director |
27/04/2026 |
| Dr. Joanne Louise Viney, PhD |
Independent Director |
27/04/2026 |
| Mr. Michael Cloonan, M.B.A. |
Chief Executive Officer, President and Director |
27/04/2026 |
| Dr. Joshua Resnick, M.B.A.,M.D. |
Independent Director |
27/04/2026 |
| Ms. Laurie D. Stelzer, M.B.A. |
Independent Director |
27/04/2026 |
| Dr. Peter A. Thompson,M.D.,F.A.C.P. |
Independent Director |
27/04/2026 |
| Dr. Bruce Booth, D.Phil. |
Independent Director |
27/04/2026 |
| Mr. Paul J. Clancy, M.B.A. |
Chairperson of the Board |
27/04/2026 |
|
|
|
|
